Title -
Sickle Cell Disease Pipeline Insights 2017
Summary
“Sickle Cell Disease Mechanism of action Insights, 2017", report provides comprehensive insights of
the ongoing therapeutic research and development across Sickle Cell Disease. The report provides a
complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage
products. A comparative pipeline therapeutics assessment of Sickle Cell Disease by development stage,
therapy type, route of administration and molecule type is also covered in the report. It also has a
special feature on the inactive pipeline products in this area.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by Diligent Market`s team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable
sources like search engines, News websites, Government Websites, Trade Journals, White papers,
Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available
databases.
The market outlook also provides understanding of country specific revenue and share by analyzing
performance of the current therapies and thorough potential uptake of new products. Additionally, the
Report highlights the frontrunners, the drivers and barriers for the Sickle Cell Disease market, as well
as treatment algorithm, current treatments & advancements are included.The chapters including
marketed products highlights the advantages and disadvantages associated with therapies associated
with Sickle Cell Disease, providing an in-depth analysis of emerging therapies which will create an
impact through their launch
Leading companies are operating in the Hypoglycemia profiled in the report are GBT, Sangmo,
Glycomimentics, Pfizer, Acceleron, Addex Therapeutics, Addmedica , Advinus Therapeutics, Alnylam
Pharmaceuticals, Angiocrine Bioscience, ArQule, Bio Products Laboratory, Bioverativ, Bluebird bio,
Bristol-Myers Squibb, Calimmune , CRISPR Therapeutics, CSL Ltd, & list continues...